ZJYL
Jin Medical International Ltd.
There isn't enough reported data to score ZJYL yet.
ZJYL Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Weak |
ZJYL's profitability is currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue and cash flow.
ZJYL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 11x | $2.19 | -43% |
| Fair | 18x | $3.67 | -5.1% |
| Current | 21x | $3.87 | — |
| Expensive | 161x | $32.23 | +733% |
Historical ranges are pointers, not guarantees.
ZJYL's PE is 21x, but its earnings don't support one, so it isn't a reliable read right now.
ZJYL Forward outlook
There aren't enough analyst estimates for ZJYL to show an outlook.
ZJYL Earnings Per Share
ZJYL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $8.9M | -9.7% |
| Q3 2025 | $10.8M | -17% |
| Q1 2025 | $9.9M | -6.4% |
| Q3 2024 | $12.9M | +35% |
| Q1 2024 | $10.6M | +3% |
| Q3 2023 | $9.6M | -1.6% |
| Q1 2023 | $10.3M | +8.3% |
| Q3 2022 | $9.7M | -14% |
ZJYL's revenue is growing: $9M last quarter, down 16% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -7.2% | -19 points |
| Q3 2025 | 9.8% | -1.6 points |
| Q1 2025 | -4.6% | -22 points |
| Q3 2024 | 19% | +7.1 points |
| Q1 2024 | 12% | +0.9 points |
| Q3 2023 | 11% | +4.5 points |
| Q1 2023 | 17% | -2.3 points |
| Q3 2022 | 11% | -1.6 points |
ZJYL's operating margin was −7.2% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
ZJYL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$2.7M | -633% |
| Q3 2025 | -$4.2M | -$2.9M |
| Q1 2025 | $510.9K | +$544.6K |
| Q3 2024 | -$1.3M | -607% |
| Q1 2024 | -$33.7K | -101% |
| Q3 2023 | $260K | -84% |
| Q1 2023 | $2.7M | +$2.8M |
| Q3 2022 | $1.6M | -19% |
ZJYL's free cash flow was −$8M over the past year, against $5M the year before.
ZJYL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +2 shares |
| 1 year | +0.1% | +7.3K shares |
| 3 years | -61% | -12.2M shares |
ZJYL has 8M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q3 2022 | — |
| Q1 2022 | — |
| Q3 2021 | — |
| Q1 2021 | — |
| Q3 2020 | — |
| Q1 2020 | — |
| Q3 2019 | — |
ZJYL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 13.4x | High |
| Q1 2025 | 2.1x | Moderate |
| Q3 2024 | 0.8x | Very low |
| Q1 2024 | 0.3x | Very low |
ZJYL's net debt is about 13 years of its operating earnings (EBITDA).
ZJYL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.7 | Neutral |
| Stochastic | 61.8 | Neutral |
ZJYL's weekly RSI is 66 (neutral) and its Stochastic is 62 (neutral).
ZJYL PE vs Healthcare Sector
| Metric | ZJYL | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 26x | 20% below |
| PE % | 55 | 39 | 16 pts above |
ZJYL is trading at 21x earnings, a 20% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ZJYL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.45 | 58% above |
| 20 week MA | $2.32 | 67% above |
| 50 week MA | $2.64 | 47% above |
| 100 week MA | $8.05 | 52% below |
ZJYL has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 52% below its 100-week average.
ZJYL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $7.45 | $248.1 | +3230% |
| 2024 | $248.1 | $21.0 | -92% |
| 2025 | $21.0 | $4.46 | -79% |
| 2026 YTD | $4.46 | $3.87 | -13% |
ZJYL's yearly returns have swung widely, from +3230% in 2023 to −92% in 2024. It's down 13% so far in 2026.